Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rostaporfin - Adgero Biopharmaceuticals

Drug Profile

Rostaporfin - Adgero Biopharmaceuticals

Alternative Names: PhotoPoint SnET2; Photrex; Purlytin; REM-001; REM-001 Therapy; Rostaporfin-PDT; Sn(IV) etiopurpurin; SnET2; SnET2-PDT; Tin ethyl etiopurpurin

Latest Information Update: 26 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer Adgero Biopharmaceuticals; Miravant Medical Technologies
  • Class Antihyperlipidaemics; Antineoplastics; Antipsoriatics; Heavy metals
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Basal cell nevus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Basal cell cancer
  • No development reported Age-related macular degeneration; Psoriasis
  • Discontinued Benign prostatic hyperplasia; Brain cancer; Coronary artery restenosis; Diabetic retinopathy; Glaucoma; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Prostate cancer; Skin cancer

Most Recent Events

  • 22 Feb 2018 REM-001 therapy receives Orphan Drug status for Basal Cell Nevus Syndrome in USA
  • 10 Apr 2017 Efficacy data from the phase II/III trials in Breast cancer released by Adgero Biopharmaceuticals
  • 05 Jan 2017 Phase-I/II clinical trials in Basal cell cancer (Recurrent) in USA (IV)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top